Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical EfficacyHoyoung Maeng, Jay A. Berzofsky, Wei‐Zen Wei et al.|Frontiers in Oncology|2021Cited by 26
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).Hoyoung Maeng, Jay A. Berzofsky, Lauren V. Wood et al.|Journal of Clinical Oncology|2019Cited by 8
597 Vaccine antigen-specific T cell responses persisted several years after initial vaccination in patients with prostate cancer who re-enrolled to a subsequent study involving multiepitope vaccinationHoyoung Maeng, Jay A. Berzofsky, William E. Becker et al.|Regular and Young Investigator Award Abstracts|2024Cited by 0